Quantification of 2,3-dihydro-7-methoxypyrrolo-[2,1-b]-quinazolin-9(1H)-one, a new antiallergic agent, by high-performance liquid chromatography in serum.
The CDRI compound 73/602 (I, 7-methoxydeoxyvasicinone) is an antiallergic agent presently undergoing Phase II clinical trials. A rapid, precise and sensitive high-performance liquid chromatographic assay has been developed and validated for the detection of I in rat serum. The method involves extraction of rat serum samples with diethyl ether after addition of 1 M potassium hydroxide. Separations were accomplished on a RP-18 column using acetonitrile-phosphate buffer (pH 7) (20:80, v/v) as the mobile phase. Recovery of I was always > 90%. An excellent linear relationship (r = 0.9999) was obtained between the quantified and added concentrations over the range of 2.5 to 500 ng/ml. The sensitivity of the assay for 0.5 ml serum was 2.5 ng/ml.
Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, India.
S K
SK
Singh
J K
JK
Paliwal
P K
PK
Grover
R C
RC
Gupta
D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000706:statistics & numerical data; D006967:Hypersensitivity / Q000188:drug therapy; D011799:Quinazolines / Q000097:blood* / Q000493:pharmacokinetics; D051381:Rats; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D011799:Quinazolines; C090638:7-methoxydeoxyvasicinone